
Aug 27, 2026
Neurophet Supplies 'Neurophet AQUA' and 'Neurophet AQUA AD Plus' to Elevate Clinic in the U.S., Expanding Its Presence in the U.S. Brain Disorders Market
Provides solutions for analyzing brain atrophy and white matter hyperintensities, as well as monitoring side effects associated with Alzheimer's disease treatmentsSecures a key reference site at a U.S. medical institution specializing in neurological disorders, accelerating product adoption across major healthcare institutions in North AmericaSEOUL, South Korea, Aug. 27, 2026 /PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company



